Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE ValGenesis, Inc.
FREMONT, Calif., June 23, 2014 /PRNewswire/ -- ValGenesis, Inc., the market leader in Enterprise Validation Lifecycle Management Solutions (VLMS) today announced that ScinoPharm Taiwan Ltd., a manufacturer of potent compound API and finished drug products, has implemented and successfully gone live with the ValGenesis VLMS 3.0 - Validation Lifecycle Management Solution to manage their validation lifecycle processes.
ScinoPharm has been seeking a software solution to manage their validation processes electronically. Upon completion of their evaluation, ScinoPharm determined that ValGenesis VLMS offered significant improvement to the current validation process in terms of increased efficiency, reduction in validation lifecycle times, improvements in regulatory compliance as well as a holistic view of validation projects. ValGenesis VLMS was selected to meet ScinoPharm's requirements and its out-of-the-box offering was implemented, validated and put into production in six weeks.
"We had evaluated various options to manage our validation process electronically and ValGenesis appears to be the correct choice for ScinoPharm, based on the process and functions that are pre-built into the solution," said Mr. Steve Johnson, Injectable Plant Project Director of ScinoPharm "ValGenesis understanding of our vision and requirements helped ScinoPharm to configure the system to meet our specific validation process requirements, especially validation of our new manufacturing facility. We have already experienced an improvement in our validation process in terms of consistency and in the reduction of the validation cycle time. We also expect the ValGenesis software solution to help us implement and enforce the validation standards and procedures that typically lie within validation master plans, SOPs and policy documents. ValGenesis' dedicated implementation team helped us implement the system in a very short period of time, which helped us meet the implementation target date."
"ScinoPharm is a rapidly growing Process R&D and API manufacturing service provider and proactively addresses this growing need by automating critical areas including validation processes," commented Dr. Siva Samy, ValGenesis' Chief Product Strategist. "ValGenesis is known for helping global companies such as ScinoPharm to manage the validation process electronically, reduce the validation cycle time, enable standardization, and enforce consistency and compliance in the corporate validation process. We are very pleased to partner with ScinoPharm and eager to continue expanding on the capabilities of the system to meet ScinoPharm's validation lifecycle management needs."
ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and Mainland China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. The Company also provides a vertically integrated, one-stop-shopping service for its API customers by expanding into the field of oncological injectable formulations. For more information, please visit the Company's website at http://www.scinopharm.com.
ValGenesis, Inc. is the provider of an innovative software platform designed to provide the foundation for compliance-based validation activities in Life Sciences companies. ValGenesis, Inc. provides the first Enterprise application to manage the corporate validation lifecycle process. Through an industry peer review committee, the Parenteral Drug Association (PDA) recognized the ValGenesis solution with its very prestigious New Innovative Technology award. The ValGenesis Suite is designed to be fully compliant with U.S. FDA 21 CFR Part 11 requirements. For more information, visit the ValGenesis website at http://www.valgenesis.com.
Mike Beaudro, Marketing Manager
ValGenesis, Inc. | 42840 Christy St. | Fremont, CA 94538
Ph: 510 445 0505 | Email
©2012 PR Newswire. All Rights Reserved.